

## PRELIMINARY AMENDMENT

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

## LISTING OF CLAIMS:

1. (original): An agent for the prevention or treatment of a disease associated with hyperglycemia, comprising as an active ingredient a selective SGLT1 inhibitor.
2. (original): An agent for the prevention or treatment as claimed in claim 1, wherein the active ingredient is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.
3. (currently amended): An agent for the prevention or treatment as claimed in claim 1-~~or 2~~, wherein the dosage form is an oral agent.
4. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1-3~~claim 1, wherein the disease associated with hyperglycemia is diabetes.
5. (original): An agent for the prevention or treatment as claimed in claim 4, wherein the diabetes is postprandial hyperglycemia.
6. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~in claim 1, wherein the disease associated with hyperglycemia is impaired glucose tolerance.
7. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~claim 1, wherein the disease associated with hyperglycemia is diabetic complications.

## PRELIMINARY AMENDMENT

8. (currently amended): An agent for the prevention or treatment as claimed in ~~any one of claims 1 to 3~~claim 1, wherein the disease associated with hyperglycemia is obesity.

9. (original): A method for the prevention or treatment of a disease associated with hyperglycemia, which comprises administering an effective amount of a selective SGLT1 inhibitor.

10. (original): A method for the prevention or treatment as claimed in claim 9, wherein the selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

11. (currently amended): A method for the prevention or treatment as claimed in claim ~~9 or 10~~, wherein the dosage form is an oral agent.

12. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is diabetes.

13. (original): A method for the prevention or treatment as claimed in claim 12, wherein the diabetes is postprandial hyperglycemia.

14. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~in claim 9, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

15. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is diabetic complications.

16. (currently amended): A method for the prevention or treatment as claimed in ~~any one of claims 9 to 11~~claim 9, wherein the disease associated with hyperglycemia is obesity;

## PRELIMINARY AMENDMENT

17. (currently amended): ~~A use of a selective SGLT1 inhibitor~~ A method for the manufacture of a pharmaceutical composition for the prevention or treatment of a disease associated with hyperglycemia; which method comprises blending the selective SGLT1 inhibitor of claim 1 with a pharmaceutically acceptable additive.

18. (currently amended): A ~~use~~ method as claimed in claim 17, wherein the selective SGLT1 inhibitor is an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect.

19. (currently amended): A ~~use~~ method as claimed in claim 17 ~~or 18~~, wherein the composition is an oral agent.

20. (currently amended): A ~~use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is diabetes.

21. (currently amended): A ~~use~~ method as claimed in claim 20, wherein the diabetes is postprandial hyperglycemia.

22. (currently amended): A ~~use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

23. (currently amended): A ~~use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is diabetic complications.

24. (currently amended): A ~~use~~ method as claimed in ~~any one of claims 17 to 19~~ claim 17, wherein the disease associated with hyperglycemia is obesity.

25. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the dosage form is an oral agent.

## **PRELIMINARY AMENDMENT**

26. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetes.

27. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetes.

28. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

29. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

30. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is diabetic complications.

31. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is diabetic complications.

32. (new): An agent for the prevention or treatment as claimed in claim 2, wherein the disease associated with hyperglycemia is obesity.

33.. (new): An agent for the prevention or treatment as claimed in claim 3, wherein the disease associated with hyperglycemia is obesity.

34. (new): A method for the prevention or treatment as claimed in claim 10, wherein the dosage form is an oral agent.

35. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetes.

36. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetes.

## PRELIMINARY AMENDMENT

37. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

38. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

39. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is diabetic complications.

40. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is diabetic complications.

41. (new): A method for the prevention or treatment as claimed in claim 10, wherein the disease associated with hyperglycemia is obesity.

42. (new): A method for the prevention or treatment as claimed in claim 11, wherein the disease associated with hyperglycemia is obesity;

43. (new): A method as claimed in claim 18, wherein the composition is an oral agent.

44. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetes.

45. (new)A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetes.

46. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

## **PRELIMINARY AMENDMENT**

47. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is impaired glucose tolerance.

48. (new): A method as claimed in claim 18, wherein the disease associated with hyperglycemia is diabetic complications.

49. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is diabetic complications.

50. (new): A use as claimed in claim 18, wherein the disease associated with hyperglycemia is obesity.

51. (new): A method as claimed in claim 19, wherein the disease associated with hyperglycemia is obesity.